Skip to main content

Advertisement

SpringerLink
Log in

Disparities in the survival improvement of recurrent breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

The therapeutic advances in breast cancer have improved the survival of patients with early disease; however, survival improvement of patients with recurrent disease remains ambiguous. In this retrospective study, we examined whether disparities in survival improvement exist in patients with recurrent breast cancer with distant metastasis.

Methods

The survival time of 126 patients who experienced recurrence at distant sites from 1990 through 1996 was compared to that of 195 patients who did from 1997 through 2003.

Results

A significant survival improvement was observed in the patients who experienced recurrence in the period of 1997–2003 in comparison to the other period in the subsets with estrogen receptor (ER)-positive disease, those who received adjuvant hormonal therapy, and those with a disease-free interval (DFI) of 24 months or more. However, no significant survival improvement was observed in each counterpart. The median survival time (MST) from the first relapse of patients with ER-positive disease in the recurrence period of 1997–2003 was 18.8 months longer than that in the recurrence period of 1990–1996 (46.6 months vs. 27.8 months). The MST of patients with a DFI of 24 months or more in 1997–2003 was 20.3 months longer than that in the other time period (47.2 months vs. 26.9 months).

Conclusion

The survival of recurrent breast cancer has improved with disparities. The ER status and the DFI are associated with a survival improvement of women with recurrent breast cancer with distant metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.

    Article  Google Scholar 

  2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.

    Article  CAS  PubMed  Google Scholar 

  3. Vogel CL, Azevedo S, Hilsenbeck S, East DR, Ayub J. Survival after first recurrence of breast cancer. The Miami experience. Cancer. 1992;70:129–35.

    Article  CAS  PubMed  Google Scholar 

  4. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44–52.

    Article  PubMed  Google Scholar 

  5. Carlson RW, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Moe RE, et al. NCCN breast cancer practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996;10:47–75.

    CAS  Google Scholar 

  6. Hébert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol. 2004;22:3685–93.

    Article  PubMed  Google Scholar 

  7. Ghersi D, Wilcken N, Simes J, Donoghue E. Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2005;(2):CD003366.

  8. Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep. 2007;9:22–30.

    Article  CAS  PubMed  Google Scholar 

  9. Anan K, Mitsuyama S, Tamae K, Suehara N, Nishihara K, Ogawa Y, et al. Postoperative follow-up of patients with early breast cancer: reappraisal of serum tumor markers. Surg Today. 2002;32:13–8.

    Article  PubMed  Google Scholar 

  10. Leon AC, Heo M. A comparison of multiplicity adjustment strategies for correlated binary endpoints. J Biopharm Stat. 2005;15:839–55.

    Article  PubMed  Google Scholar 

  11. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974–84.

    Article  CAS  PubMed  Google Scholar 

  12. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996;88:1543–9.

    Google Scholar 

  13. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451–67.

    Google Scholar 

  14. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802.

    Article  CAS  PubMed  Google Scholar 

  15. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Austrian Breast and Colorectal Cancer Study Group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99:1845–53.

    Google Scholar 

  16. Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2007;(1):CD003370.

  17. Vassilomanolakis ME, Tsoussis S, Kandylis K, Hajichristou E, Efremidis AP. Rechallenge by tamoxifen in metastatic breast cancer. Prospective study of different dose levels. Breast Dis. 1991;4:129–34.

    Google Scholar 

  18. Itoh Y, Tanaka H, Iwase H, Karamatsu S, Yamashita H, Itoh K, et al. Readministration of tamoxifen after adjuvant therapy for recurrent breast cancer. Breast Cancer. 2000;7:149–52.

    Article  CAS  PubMed  Google Scholar 

  19. Muss HB, Smith LR, Cooper MR. Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. J Clin Oncol. 1987;5:1556–8.

    CAS  PubMed  Google Scholar 

  20. Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol. 1993;11:345–50.

    CAS  PubMed  Google Scholar 

  21. Pyrh S, Valavaara R, Vuorinen J, Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat. 1994;29:223–8.

    Article  Google Scholar 

  22. Clinton OP, Priestman TJ, Latief TN, Earl H, Murphy A, Blackledge GR, et al. A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer. Clin Oncol (R Coll Radiol). 1995;7:251–6.

    CAS  Google Scholar 

  23. Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, et al. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. J Clin Oncol. 1997;15:3141–8.

    CAS  PubMed  Google Scholar 

  24. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22:3302–8.

    Article  PubMed  Google Scholar 

  25. No authors listed. NCCN antiemesis practice guidelines. Oncology (Williston Park). 1997;11:57–89.

  26. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17:2971–94.

    CAS  PubMed  Google Scholar 

  27. Hesketh PJ. Treatment of chemotherapy-induced emesis in the 1990 s: impact of the 5-HT3 receptor antagonists. Support Care Cancer. 1994;2:286–92.

    Article  CAS  PubMed  Google Scholar 

  28. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986;319:230–4.

    Article  CAS  PubMed  Google Scholar 

  29. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med. 2001;344:783–92.

    Article  CAS  PubMed  Google Scholar 

  30. Baar J. Biological therapy of breast cancer: Recent clinical applications. Curr Opin Investig Drugs. 2007;8:987–95.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Kitakyushu Municipal Medical Center, Bashaku 2-1-1, Kokurakita-ku, Kitakyushu, Fukuoka, 802-0077, Japan

    Keisei Anan, Shoshu Mitsuyama, Kenichirou Koga, Reiko Tanabe, Michiyo Saimura, Yoshitaka Tanabe, Masato Watanabe, Nobuhiro Suehara, Hiroaki Matsunaga, Kazuyoshi Nishihara, Yuji Abe, Toru Nakano & Keiyoshi Tamae

  2. Department of Radiology, Kitakyushu Municipal Medical Center, Bashaku 2-1-1, Kokurakita-ku, Kitakyushu, Fukuoka, 802-0077, Japan

    Minoru Ono

  3. Department of Pathology, Kitakyushu Municipal Medical Center, Bashaku 2-1-1, Kokurakita-ku, Kitakyushu, Fukuoka, 802-0077, Japan

    Satoshi Toyoshima

Authors
  1. Keisei Anan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shoshu Mitsuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenichirou Koga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reiko Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michiyo Saimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitaka Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masato Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobuhiro Suehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroaki Matsunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuyoshi Nishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yuji Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Toru Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Keiyoshi Tamae
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Minoru Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Satoshi Toyoshima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keisei Anan.

About this article

Cite this article

Anan, K., Mitsuyama, S., Koga, K. et al. Disparities in the survival improvement of recurrent breast cancer. Breast Cancer 17, 48–55 (2010). https://doi.org/10.1007/s12282-009-0103-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-009-0103-2

Keywords

Search

Navigation